About
Drug Discovery Software, Knowledgebases +
Eidogen-Sertanty is dedicated to improving health, medicine, and general well-being. For over 12-years, Eidogen-Sertanty has been helping the discovery of new, safer medicines through innovative software technology, knowledgebases, and collaborative projects. Eidogen-Sertanty's solutions bridge the knowledge gap between biology and chemistry, and service engagements help to accelerate the drug discovery process.
Since 2003, we have worked with every top pharmaceutical and biopharmaceutical company in the world across the alphabet of chronic and acute disease. Through our product and service offerings, Eidogen-Sertanty proudly has helped companies make advances in numerous disease areas including cancer, AIDS, arthritis, general infection, and pain.
Our major discovery informatics platforms TIP™, ChIP™, and Kinase Knowledgebase™ allow our pharmaceutical clients and partners to leverage public and proprietary chemical and structural knowledge to substantially improve the overall efficiency of the drug discovery cycle from hit to lead, increasing the odds and lowering the costs of successfully developing novel, safe, and effective medicines.
Our DirectDesign™ Discovery Service combines all of our proprietary technologies for the directed de novo design of lead compounds and target-focused virtual libraries. Our biotechnology and pharmaceutical clients utilize DirectDesign to fully exploit the complete spectrum of Eidogen-Sertanty's knowledge-driven discovery informatics capabilities on a project-by-project basis.
Foundation Models +
Our foundation models answer comparative questions, because that is the question a project actually asks: which of two compounds a protein prefers, and which of two proteins a compound prefers. Nothing is docked and no structure is needed. Each returns a ranking and a prediction strength whose reliability was measured on held-out data.
Family Foundation Model. The broad instrument: two separately fitted models over 34 protein families, trained on ChEMBL 37 alone, so the weights are freely downloadable. 0.71 over 65,725 held-out comparisons at 2,079 targets, and 0.75 over 8,689 at 1,879.
GPCR Foundation Model. A deep dive into G protein-coupled receptors, on ChEMBL together with Eidogen-curated data. 0.77 on potency and 0.80 on selectivity, rising to 0.94 and 0.93 on the confident calls.
Kinase Foundation Model. The deep dive with the deepest data behind it, trained on the Kinase Knowledgebase. 0.69 on potency and 0.75 on selectivity, rising to 0.88 and 0.92 on the confident calls.
Board of Directors +
Steven Muskal, Ph.D.
Chief Executive Officer
Dr. Steven Muskal, founder of Sertanty, Inc. and Chief Executive Officer of Eidogen-Sertanty, has over 30 years of industry experience in technology development and marketing in the biopharmaceutical community. Before establishing Sertanty, Dr. Muskal served as the Chief Technology Officer and Vice President of Informatics for Libraria, Inc., helping to secure financing while responsible for technology development and operational activity. Before joining Libraria, he served as Unit Director at the Affymax Research Institute and as a member of the Glaxo Wellcome Scientific Computing Board. At Affymax, Dr. Muskal directed departments focusing on advanced technologies in parallel synthesis, lead optimization (ADME), and research computing. Previously, he held positions as Product Manager, Senior Scientist, and Applications Scientist at MDL Information Systems, while designing, developing, and marketing chemical informatics software.
Dr. Muskal received his Doctorate in Biophysical Chemistry from the University of California, Berkeley and his B.Sc. in Engineering Chemistry and Computer Science from the Colorado School of Mines. He is a triathlete, plays amateur baseball, and is a drummer.
Shehan Dissanayake, Ph.D.
Director
Dr. Shehan Dissanayake is the CEO of Tavistock Life Sciences. He oversees all of TLS's operations and portfolio companies, including its investments in Eidogen-Sertanty, CovX, and Kalypsys. Prior to joining TLS, Shehan served as partner in charge of Strategy and Business Planning for Andersen's Global Tax, Human Resource, and Legal operating unit. Shehan received his B.A. in Biology and Chemistry at Skidmore College and a Ph.D. in Cell Physiology from The University of Chicago.
Chris Fuglesang, Ph.D.
Director
Dr. Fuglesang joined Tavistock Life Sciences in 2005. He has responsibilities for portfolio intellectual property, the management of existing portfolio companies, and the identification of prospective public and private investments. Prior to joining Tavistock, Dr. Fuglesang was Vice President at Eidogen, a structural proteomics software company, and a practicing attorney at Perkins Coie LLC in their biotechnology practice group. Dr. Fuglesang received a B.S. in both Chemistry and Physics from the University of California at Los Angeles, a Ph.D. in Theoretical Chemical Physics from the University of California at Los Angeles, and a J.D. from Boston University.
Roy Thiele-Sardiña
Director
Roy Thiele-Sardiña has over 35 years of computer technology experience. He was co-founder of Tasmania Network Systems, a cache proxy company that was acquired by Cisco Systems and a member of the founding management team for Brocade Communications Systems. Prior to Brocade, Mr. Thiele-Sardiña was responsible for Sun Microsystems's Corporate Development Organization in the office of the Chairman. Mr. Thiele-Sardiña holds Bachelor of Science degrees in Electrical Engineering and Computer Science from the University of Wisconsin-Madison, and an M.B.A. from New York University, Stern School of Business.
Guillermo Surraco
Director
Guillermo Surraco joined Technofyn Associates LLC as an Associate in 2000. Technofyn Associates LLC is an investment and venture capital firm whose principal owner is Dr. Alejandro Zaffaroni. Previously, Guillermo worked in the areas of marketing and sales for HSQ Technology and Landis & Gyr Systems Inc. He received a BS in Mechanical Engineering from Santa Clara University.
Malcolm Cloyd
Director
Malcolm Cloyd is a founder and managing member of the Athenaeum Fund. He has served as President, Vice President and General Manager of manufacturing and service businesses with domestic and international markets for over 27 years. He has directed business units that were the largest cash contributors for two major corporations and has conducted turnarounds of under-performing businesses for both large corporations and privately held companies. Mr. Cloyd has degrees in management, science and literature.
Investors +
Tavistock Life Sciences
Tavistock Life Sciences Inc. is a division of the Tavistock Group. Tavistock Life Sciences invests in a select number of biotech opportunities with exceptional technology profiles. In each biotech investment, Tavistock Life Sciences assumes an active partnership role providing appropriate financing, strategic and operational planning, business development, and recruiting assistance. More...
HighBAR Ventures
HighBAR Ventures is a group of investors including Bill Joy, Andreas Bechtolsheim, and Roy Thiele-Sardiña, founders and investors in several companies including Sun Microsystems, Brocade Communications, and Google.
Alejandro Zaffaroni
Dr. Zaffaroni is a world renowned scientist, entrepreneur, and life sciences investor who has founded numerous successful life sciences companies, including ALZA, DNAX, Affymax, Affymetrix, Symyx, Maxygen, and Alexza.
The Athenaeum Fund
The Athenaeum Fund is a venture capital limited partnership comprised of a General Partner and sixty-five Limited Partners who provide seed funding to emerging Southern California technology companies. More...
Band of Angels
The Band of Angels is Silicon Valley's oldest organization still dedicated exclusively to funding and advising seed stage startups. The Band is a formal group of 100 former and current high tech executives who are interested in investing their time and money into new, cutting edge, startup companies. Band members have founded companies such as Symantec, Logitech, and National Semiconductor and been senior executives at the likes of Sun Microsystems, Hewlett Packard, and Intuit. More...
Partners +
Dassault Systèms - BIOVIA
BIOVIA has been delivering software and service solutions to pharmaceutical, biotechnology, and industrial chemical research organizations for over twenty years. With expertise in life and materials science modeling and simulations, informatics, nanotechnology and scientific operating platform technology, BIOVIA's multi-disciplinary solutions span the research and development continuum. More...
ChemAxon
ChemAxon provides cheminformatics software development platforms and applications for life science research. Their core capabilities include platform and desktop solutions for structure visualization, search and management, property prediction, clustering, virtual synthesis, screening and drug design. More...
InfoChem GmbH
InfoChem GmbH, a software company based in Munich, has focused on the production and commercial marketing of new chemical information products since its foundation in 1989. InfoChem's main activities involve the development of software and databases for the storage and handling of structural and reaction databases for organic and pharmaceutical chemistry. InfoChem's customers are the big chemical and pharmaceutical companies worldwide. InfoChem's customers are the large chemical and pharmaceutical companies as well as small high potential start ups worldwide. More...
Intel
Intel (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world's computing devices. Additional information about Intel is available at newsroom.intel.com and blogs.intel.com
Molecular Materials Informatics
Molecular Materials Informatics provides cheminformatics software for mobile computing environments. The flagship product is the Mobile Molecular DataSheet (MMDS), which combines a unique and innovative chemical diagram sketcher with informatics features for organizing molecular datasheets, accessing chemically aware webservices, and sharing data using network resources. More...
Molecular Networks
Molecular Networks provides multifaceted, innovative software to the chemical, biotechnology, and pharmaceutical industry. The company's suite of chemoinformatics applications covers many different areas including handling of chemical information, design of new chemical entities, and prediction of physicochemical and biological properties of chemical compounds. Molecular Networks is leveraging its know-how and proprietary technology to expand its business activities in the area of synthesis driven combinatorial library design, prediction of synthetic accessibility of compounds, and prediction of enzyme-mediated chemical transformations. More...
Oracle Corporation
Oracle Corporation is the world's largest enterprise software company, providing enterprise software to the world's largest and most successful businesses. With annual revenues of more than $10.8 billion, the company offers its database, tools and application products, along with related consulting, education, and support services. More...
Specs
Specs is one of the world's leading suppliers of screening compounds and research chemicals (Building Blocks and Natural Products) to the Life Science industry. Specs' repository is built through global acquisition programs utilizing a network of more than 20,000 researchers working in universities and institutes around the world. Each month, 5,000 to 10,000 carefully selected novel compounds from all over the world are added to the dynamic collection. From its headquarters in Delft, The Netherlands, Specs manages its global activities through regional offices and representatives in North America, Japan, India and China. More...